Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly xanomeline 75 mg t.i.d. for Alzheimer's shows efficacy in Phase II, California Clinical Trials official says.

Executive Summary

LILLY XANOMELINE 75 MG T.I.D. FOR ALZHEIMER's SHOWS EFFICACY IN PHASE II, according to California Clinical Trials researcher Neal Cutler, MD. Cutler spoke June 26 at the Drug Information Association annual meeting in Orlando. A 373-patient double-blind placebo-controlled study of Alzheimer's patients found that of three doses tested -- 25, 50, and 75 mg t.i.d. -- the 75 mg dose showed efficacy measured by the ADAS-CoG scale and nurse observation.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS026495

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel